Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | SHBG | P04278 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204024 | 1.00 | LMNA (1.00) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL6220484 | 0.90 | LMNA (0.81) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL312243 | 0.90 | ESR1 (1.00) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL30503014 | 0.90 | ESR1 (1.00) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL29514772 | 0.83 | ESR1 (0.81) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL3958571 | 0.83 | LMNA (1.00) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL3586687 | 0.83 | ESR1 (0.81) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL22672221 | 0.83 | ESR1 (0.81) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL38652384 | 0.83 | ESR1 (0.81) | LMNARAB9AMAPTNPC1GAA | |
| SCHEMBL3820741 | 0.83 | ESR1 (0.81) | LMNARAB9AMAPTNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020231979-A9 | SMALL MOLECULE INHIBITORS OF VIRAL REPLICATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020231979-A1 | SMALL MOLECULE INHIBITORS OF VIRAL REPLICATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-11-19 | — | — | WO | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2533638-B1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9187447-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-1542675-A4 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7368434-B2 | Compounds useful for the inhibition of ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1542675-A1 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | The Endowment For Research In Human Biology, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040068003-A1 | Compounds useful for the inhibition of ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC, | 2004-04-08 | — | — | US | disclosed |
| WO-2004002470-A1 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | LMNA 3282/4885RAB9A 812/4885MAPT 3520/4885 |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | LMNA 4728/4885RAB9A 3507/4885MAPT 3463/4885 |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | LMNA 4728/4885RAB9A 3507/4885MAPT 3463/4885 |
| US-20040068003-A1 | Compounds useful for the inhibition of ALDH | ALDH2, ALDH1A1, ALDH3A1 | LMNA 4826/4885RAB9A 2663/4885MAPT 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.